RBC Capital Starts Eagle Pharmaceuticals (EGRX) at Outperform
Tweet
Share
E-mailGet Alerts EGRX Hot Sheet
Price: $2.14 --0%
Rating Summary:
2 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Rating Summary:
2 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 23 | New: 12
Join SI Premium – FREE
RBC Capital initiated coverage on Eagle Pharmaceuticals (NASDAQ: EGRX) with an Outperform rating and a price target of $97.00.
For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.
Shares of Eagle Pharmaceuticals closed at $84.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Craig-Hallum Starts Alterity Therapeutics (ATHE) at Buy
- JPMorgan Resumes Take-Two Interactive (TTWO) at Overweight
- Rapid7 (RPD) PT Raised to $12 at RBC Capital
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
